International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-1 doi: 10.5281/zenodo.10606412
Original Article
Correlation of Neutrophil Lymphocyte Ratio with COPD Assessment Score (CAT)
 ,
 ,
Published
Jan. 29, 2024
Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a complex respiratory condition characterized by airflow limitation and systemic inflammation. The COPD Assessment Test (CAT) is an established tool for evaluating the impact of COPD on patient health status. Recent studies have suggested that the Neutrophil Lymphocyte Ratio (NLR) may reflect systemic inflammation and predict exacerbations in COPD.

Objective: To establish the correlation between NLR and CAT scores in COPD patients and to evaluate the potential of NLR as a biomarker for disease severity.

Methods: This cross-sectional observational study included 45 COPD patients. NLR was calculated from complete blood counts, and CAT scores were obtained. Pearson’s correlation coefficient was used to analyze the relationship between NLR and CAT scores.

Results: The mean NLR was 3.5 ± 1.3, and the mean CAT score was 18.2 ± 5.6. A significant positive correlation was found between NLR and CAT scores (r=0.68, p<0.001). Higher NLR values were associated with higher CAT scores, particularly in the highest CAT score category (>20), which had a mean NLR of 4.2 ± 1.1 (p<0.001).

Conclusion: The study provided evidence for a significant positive correlation between NLR and CAT scores, suggesting that NLR could be a valuable biomarker for COPD severity and patient health status impact. These findings reinforce the role of systemic inflammation in COPD and support the potential use of NLR in routine clinical assessment.

Recommended Articles
Loading Image...
Volume-5, Issue-1
Citations
1638 Views
82 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved